YOLFTbeta
41

Taiwan Advance Bio-Pharmaceutical Inc.

4186 · TWO · Healthcare / Biotechnology

6.83TWD+0.20 (+3.02%)

Price History

Full chart

Market Stats

Previous Close6.63
Open6.63
Day Range6.30 – 6.83
52-Week Range6.73 – 13.75
Volume129.41K
Market Cap652.50M
P/E (TTM)42.65
Forward P/E0.00
EPS0.17
Dividend Yield0.00%
Beta0.32
50-Day Avg7.88
200-Day Avg9.93

About

Taiwan Advance Bio-Pharmaceutical Inc. operates in the biotechnology industry in China, Germany, USA, Italy, Malaysia, Vietnam, Thailand, Indonesia, Japan, Korea, India, Pakistan, and internationally. The company provides food safety diagnostic testing kits; ELISA and rapid test kits customization, and food safety lab establishment consultation services; and manufactures monoclonal and polyclonal antibody products. It also offers stem cell banking services for newborn and adult stem cells storage; cell therapy programs; abused drugs rapid tests; operates drug testing center for urine drug test, hair drug test, and identification of drug abuse. The company also involves in research, development, production, and sales of veterinary drug residue testing reagents, drug abuse certification testing services and management, detection, extraction, cryopreservation and storage, and gene testing services for umbilical cord blood stem cells, umbilical cord mesenchymal stem cells, peripheral blood stem cells, and related businesses. Taiwan Advance Bio-Pharmaceutical Inc. was founded in 1989 and is based in Taipei, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Wen-Long Su
  • Employees160
  • HeadquartersNo. 363, Section 2, Taipei, Taiwan, Taiwan
  • Websitehttps://www.biotest.com.tw

Leadership

  • Mr. Wen-Long SuPresident & Chairman of the Board

Financials

Income Statement

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue205.80M235.57M243.36M318.24M315.98M354.17M364.79M
Growth (%)-+14.47%+3.31%+30.77%-0.71%+12.09%+3.00%
Cost of Revenue94.24M108.03M118.57M125.66M117.53M110.21M130.72M
Gross Profit111.56M127.55M124.79M192.58M198.46M243.97M234.07M
Gross Margin54.21%54.14%51.28%60.51%62.81%68.88%64.16%
Operating Expense266.54M218.28M227.61M184.97M194.19M199.13M196.68M
Operating Income-154.97M-90.73M-102.82M7.61M4.27M44.84M37.39M
Operating Margin-75.30%-38.52%-42.25%2.39%1.35%12.66%10.25%
EBITDA-138.08M-39.18M-76.69M38.00M21.81M50.65M53.37M
EBITDA Margin-67.10%-16.63%-31.51%11.94%6.90%14.30%14.63%
Net Income-174.67M-86.39M-118.53M3.17M-10.68M22.88M28.05M
Net Income Margin-84.87%-36.67%-48.70%1.00%-3.38%6.46%7.69%
R&D67.30M39.34M45.51M16.14M16.72M18.49M13.34M
R&D as % of Total Revenue32.70%16.70%18.70%5.07%5.29%5.22%3.66%
Interest Expense10.11M10.44M7.43M6.13M7.30M7.42M6.52M
Interest Expense % of Total Revenue4.91%4.43%3.05%1.93%2.31%2.10%1.79%

Balance Sheet

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets655.07M823.45M713.74M706.77M748.57M676.42M746.74M
Total Liabilities270.00K464.55M472.29M462.13M514.65M419.98M461.64M
Total Equity195.20M358.90M241.45M244.64M233.92M256.44M285.10M
Cash106.25M236.89M159.69M158.56M182.14M106.32M140.74M
Total Debt268.37M274.39M256.26M290.79M320.13M235.62M-
Net Debt162.11M37.50M96.56M132.24M138.00M129.30M125.76M

Cash Flow

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-150.75M-50.33M-48.08M-20.59M12.61M8.33M53.13M
Investing Cash Flow-29.38M-54.45M-15.20M-8.83M-13.70M-2.22M-
Financing Cash Flow216.20M235.41M-13.92M28.28M24.67M-81.92M-
Capital Expenditure46.46M55.68M14.20M7.28M11.94M3.96M33.36M
Free Cash Flow-197.21M-106.00M-62.29M-27.87M667.00K4.37M19.77M
FCF to OCF130.82%210.64%129.54%135.35%5.29%52.44%37.21%

Key Statistics & Ratios

Market Cap652.50M
Enterprise Value806.75M
Trailing P/E42.65
Forward P/E0.00
Price / Sales1.87
Price / Book2.48
EPS0.17
Book Value2.98
Revenue (TTM)348.54M
Gross Profit (TTM)213.66M
EBITDA40.89M
Profit Margin4.52%
Operating Margin-7.95%
Return on Equity6.05%
Return on Assets2.32%
Shares Outstanding90.00M
Shares Float63.50M
Beta0.32
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%